Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Chromoblastomycosis

2016; American Society for Microbiology; Volume: 30; Issue: 1 Linguagem: Inglês

10.1128/cmr.00032-16

1098-6618

Flávio Queiroz‐Telles, Sybren de Hoog, Daniel Wagner de Castro Lima Santos, Cláudio Guedes Salgado, Vânia Aparecida Vicente, Alexandro Bonifáz, Emmanuel Roilides, Liyan Xi, Conceição de Maria Pedrozo e Silva de Azevedo, Moisés Batista da Silva, Zoe Dorothea Pana, Arnaldo Lopes Colombo, Thomas J. Walsh,

Plant Pathogens and Fungal Diseases

Chromoblastomycosis (CBM), also known as chromomycosis, is one of the most prevalent implantation fungal infections, being the most common of the gamut of mycoses caused by melanized or brown-pigmented fungi. CBM is mainly a tropical or subtropical disease that may affect individuals with certain risk factors around the world. The following characteristics are associated with this disease: (i) traumatic inoculation by implantation from an environmental source, leading to an initial cutaneous lesion at the inoculation site; (ii) chronic and progressive cutaneous and subcutaneous tissular involvement associated with fibrotic and granulomatous reactions associated with microabscesses and often with tissue proliferation; (iii) a nonprotective T helper type 2 (Th2) immune response with ineffective humoral involvement; and (iv) the presence of muriform (sclerotic) cells embedded in the affected tissue. CBM lesions are clinically polymorphic and are commonly misdiagnosed as various other infectious and noninfectious diseases. In its more severe clinical forms, CBM may cause an incapacity for labor due to fibrotic sequelae and also due to a series of clinical complications, and if not recognized at an early stage, this disease can be refractory to antifungal therapy.